Home » Newsletters » BioWorld Science

BioWorld Science

May 3, 2000

View Archived Issues

Coulter and SB modify Bexxar collaboration; phase II combination trial commences

Positive effects of sildenafil in female sexual dysfunction following hysterectomy

In vivo pharmacological profile of antiplatelet agent CS-747

New series of tachykinin antagonists described in patent literature by Pfizer

New motilin receptor antagonists in the Chugai pipeline

Effective, nonulcerogenic antiarthritic agents designed by Almirall Prodesfarma

Combination of angiotensin antagonist and antiplatelet agent synergistic in thrombosis, hypertension

Ono describes use of pranlukast for sinusitis

Novel 5-HT receptor agonists from Cerebrus especially useful for obesity

Benzoylguanidines synthesized at Boehringer Ingelheim as Na+/H+ exchange inhibitors

Patent licensed to GenStar covers gene therapy for sensitizing tumors to radiation

Immtech and Tufts studying new drug for common water-borne human parasites

Progesterone vaginal gel preferable to oral capsules as regards pharmacokinetics

Caspase inhibition slows ALS onset and improves survival in mice

GW-433908/VX-175: design of excipient-free form of amprenavir

Adverse effects reported for ziconotide, a treatment for pain and for spasticity

Trial demonstrates superior efficacy of amiodarone in treating atrial fibrillation

Sleep apnea linked to increased risk of hypertension

Temacrazine exerts anti-HIV activity by inhibiting initiation of virus transcription

Nucleoside analogue and prodrug show promise as antipoxvirus agents

Chiron team identifies promising treatment for retinitis pigmentosa

Development of glycine antagonist for stroke discontinued by Glaxo Wellcome

News from ARVO: antiglaucoma activity of p160ROCK kinase inhibitor

Effects of Japanese herbal medicine on IL-10 and IL-12 production evaluated in vivo

Asthma therapy will be codeveloped by Magainin and Genentech

Addition of thymosin alpha 1 to interferon therapy may improve outcome in chronic HCV

NeoPharm files IND for antibody-targeted toxin

Merck isolates new antifungal agent that specifically inhibits glucan synthesis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...